You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR IOPAMIDOL-300


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for IOPAMIDOL-300

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated ABX CRO Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated ABX-CRO Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated Averion International Corporation Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for IOPAMIDOL-300

Condition Name

Condition Name for IOPAMIDOL-300
Intervention Trials
Coronary Artery Stenosis 3
Diabetes Mellitus 2
Coronary Artery Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for IOPAMIDOL-300
Intervention Trials
Renal Insufficiency 6
Coronary Disease 3
Renal Insufficiency, Chronic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for IOPAMIDOL-300

Trials by Country

Trials by Country for IOPAMIDOL-300
Location Trials
United States 20
Italy 2
China 2
Canada 2
Singapore 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for IOPAMIDOL-300
Location Trials
New Jersey 10
California 2
North Carolina 2
Illinois 2
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for IOPAMIDOL-300

Clinical Trial Phase

Clinical Trial Phase for IOPAMIDOL-300
Clinical Trial Phase Trials
Phase 4 16
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for IOPAMIDOL-300
Clinical Trial Phase Trials
Completed 15
Recruiting 5
Terminated 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for IOPAMIDOL-300

Sponsor Name

Sponsor Name for IOPAMIDOL-300
Sponsor Trials
Bracco Diagnostics, Inc 8
GE Healthcare 6
i3 Statprobe 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for IOPAMIDOL-300
Sponsor Trials
Industry 27
Other 22
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.